Focal Therapeutics

The Focal Therapeutics company specializes in production of medical devices in the field of an onkokhirurgiya. One of products is the implant of BioZorb which increases efficiency of diagnostic methods of inspection of a breast and radiation therapy after removal of a tumor of a breast cancer. The company was founded in 2007 and is based in California, the USA.

History

2018: Hologic purchased Focal Therapeutics

On September 27, 2018 the Hologic company signed the agreement on acquisition of Focal Therapeutics for $125 million. The transaction will be closed at the beginning of October.

Under the terms of the reached agreement, Hologic will get access to BioZorb implanted to a surgical marker which helps clinical physicians to reveal signs of a recurrence of a breast cancer after organ-preserving transactions. After removal of a tumor by the surgeon in a mammary gland cicatricial fabric which can interfere with timely detection of early signs of a recurrence of a disease is formed.

Implant of BioZorb which increases efficiency of diagnostic methods of inspection of a breast and radiation therapy after removal of a tumor of a breast cancer

The secondary tumor develops in 80% in close proximity to deleted therefore for radiologists it is so important to have the effective predictive tool in an arsenal. The BioZorb device is implanted into a mammary gland during operation on removal of primary tumor. This surgical marker provides accurate visualization (3D) specific section of a mammary gland, improving efficiency of the subsequent diagnostic inspections - mammographies, ultrasonography, MPT, KT and providing directional effect of radiation therapy. Over time the implant resolves, and tissue of a mammary gland begins to live.

Within the last 12 months before the declaration about Focal Therapeutics sales the company received about $16 million revenue. Acquisition, as expected, not especially will affect the profit of Hologic, however afterwards income will raise. In addition to Focal Therapeutics, the company also purchased the developer of the radiological Faxitron systems in 2018.^[1]

Notes